Analysis of the risk factors of radiation pneumonitis and the predictive ability of dosiomics in non-small-cell lung cancer

References

• Higgins KA , PuriS, GrayJE. Systemic and radiation therapy approaches for locally advanced non–small-cell lung cancer. J. Clin. Oncol.40(6), 576–585 (2022).
   PubMed Web of Science ®Google Scholar
• Antonia SJ , VillegasA, DanielDet al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N. Engl. J. Med.377(20), 1919–1929 (2017).
   PubMed Web of Science ®Google Scholar
• Shintani T , KishiN, MatsuoYet al. Incidence and risk factors of symptomatic radiation pneumonitis in non-small-cell lung cancer patients treated with concurrent chemoradiotherapy and consolidation durvalumab. Clin. Lung Cancer22(5), 401–410 (2021).
   PubMed Web of Science ®Google Scholar
• Palma DA , SenanS, TsujinoKet al. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. Int. J. Radiat. Oncol. Biol. Phys.85(2), 444–50 (2013).
   PubMed Web of Science ®Google Scholar
• Ren W , LiangB, SunCet al. Dosiomics-based prediction of radiation-induced hypothyroidism in nasopharyngeal carcinoma patients. Phys. Med.89, 219–225 (2021).
   PubMed Web of Science ®Google Scholar
• Liang B , YanH, TianYet al. Dosiomics: extracting 3D spatial features from dose distribution to predict incidence of radiation pneumonitis. Front. Oncol.9, 269 (2019).
   PubMed Web of Science ®Google Scholar
• Rossi L , BijmanR, SchillemansWet al. Texture analysis of 3D dose distributions for predictive modelling of toxicity rates in radiotherapy. Radiother. Oncol.129(3), 548–553 (2018).
   PubMed Web of Science ®Google Scholar
• van Griethuysen JJM , FedorovA, ParmarCet al. Computational radiomics system to decode the radiographic phenotype. Cancer Res.77(21), e104–e107 (2017).
   PubMed Web of Science ®Google Scholar
• Dossun C , NiederstC, NoelG, MeyerP. Evaluation of DIR algorithm performance in real patients for radiotherapy treatments: a systematic review of operator-dependent strategies. Phys. Med.101, 137–157 (2022).
   PubMed Web of Science ®Google Scholar
• Weichselbaum RR , LiangH, DengL, FuY-X. Radiotherapy and immunotherapy: a beneficial liaison?Nat. Rev. Clin. Oncol.14(6), 365–379 (2017).
   PubMed Web of Science ®Google Scholar
• McLaughlin M , PatinEC, PedersenMet al. Inflammatory microenvironment remodelling by tumour cells after radiotherapy. Nat. Rev. Cancer20(4), 203–217 (2020).
   PubMed Web of Science ®Google Scholar
• Fiorica F , BelluominiL, StefanelliAet al. Immune checkpoint inhibitor nivolumab and radiotherapy in pretreated lung cancer patients: efficacy and safety of combination. Am. J. Clin. Oncol.41(11), 1101–1105 (2018).
   PubMed Web of Science ®Google Scholar
• Ratnayake G , ShankerM, RobertsKet al. Prior or concurrent radiotherapy and nivolumab immunotherapy in non-small cell lung cancer. Asia Pac. J. Clin. Oncol.16(1), 56–62 (2020).
   PubMed Web of Science ®Google Scholar
• Bestvina CM , PointerKB, KarrisonTet al. A phase 1 trial of concurrent or sequential ipilimumab, nivolumab, and stereotactic body radiotherapy in patients with stage IV NSCLC study. J. Thorac. Oncol.17(1), 130–140 (2022).
   PubMed Web of Science ®Google Scholar
• Theelen WSME , PeulenHMU, LalezariFet al. Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial. JAMA Oncol.5(9), 1276–1282 (2019).
   PubMed Web of Science ®Google Scholar
• Shaverdian N , LisbergAE, BornazyanKet al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol.18(7), 895–903 (2017).
   PubMed Web of Science ®Google Scholar
• Li M , GanL, SongA, XueJ, LuY. Rethinking pulmonary toxicity in advanced non-small cell lung cancer in the era of combining anti-PD-1/PD-L1 therapy with thoracic radiotherapy. Biochim. Biophys. Acta Rev. Cancer1871(2), 323–330 (2019).
   PubMed Web of Science ®Google Scholar
• Geng Y , ZhangQ, FengSet al. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis. Cancer Med.10(4), 1222 (2021).
   PubMed Web of Science ®Google Scholar
• Placidi L , CusumanoD, LenkowiczJ, BoldriniL, ValentiniV. On dose cube pixel spacing pre-processing for features extraction stability in dosiomic studies. Phys. Med.90, 108–114 (2021).
   PubMed Web of Science ®Google Scholar
• Buizza G , PaganelliC, D’IppolitoEet al. Radiomics and dosiomics for predicting local control after carbon-ion radiotherapy in skull-base chordoma. Cancers (Basel).13(2), 339 (2021).
   PubMed Web of Science ®Google Scholar
• Qin Y , ZhuL-H, ZhaoW, WangJ-J, WangH. Review of radiomics- and dosiomics-based predicting models for rectal cancer. Front. Oncol.12, DOI: 10.3389/fonc.2022.913683 (2022).
   Google Scholar
• Jin X , ZhengX, ChenDet al. Prediction of response after chemoradiation for esophageal cancer using a combination of dosimetry and CT radiomics. Eur Radiol29(11), 6080–6088 (2019).
   PubMed Web of Science ®Google Scholar
• Bi J , QianJ, YangDet al. Dosimetric risk factors for acute radiation pneumonitis in patients with prior receipt of immune checkpoint inhibitors. Front. Immunol.12, 828858 (2022).
   PubMedGoogle Scholar
• Lee SH , HanP, HalesRKet al. Multi-view radiomics and dosiomics analysis with machine learning for predicting acute-phase weight loss in lung cancer patients treated with radiotherapy. Phys. Med. Biol.65(19), DOI: 10.1088/1361-6560/ab8531 (2020).
   Web of Science ®Google Scholar
• Ren W , LiangB, SunCet al. Dosiomics-based prediction of radiation-induced hypothyroidism in nasopharyngeal carcinoma patients. Phys. Med.89, 219–225 (2021).
   PubMed Web of Science ®Google Scholar